Evidence map›Paper›PMID 42203198›Full record

ArticleMolecular pharmaceutics2026

Assays for Measuring the Cell Permeability of Proteolysis-Targeting Chimeras (PROTACs): Performance, Correlations, Applicability and Recommendations.

Christina Brenner, Yunhai Cui, Denis Schmidt, Johannes Kirchmair, Lu Tan, Nina Braun

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christina BrennerDrug Discovery Sciences, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer Gasse 5-11, Vienna A-1121, Austria.
Yunhai CuiDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riß 88400, Germany.ORCID 0000-0003-4969-072X
Denis SchmidtMedicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riß 88400, Germany.ORCID 0000-0001-7319-3462
Johannes KirchmairDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, Vienna 1090, Austria.ORCID 0000-0003-2667-5877
Lu TanDrug Discovery Sciences, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer Gasse 5-11, Vienna A-1121, Austria.
Nina BraunDrug Discovery Sciences, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer Gasse 5-11, Vienna A-1121, Austria.ORCID 0000-0002-4697-4690

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most Proteolysis-Targeting Chimeras (PROTACs) are beyond-Rule-of-Five compounds, and optimizing their ability to cross cell membranes is a central topic in PROTAC therapeutic research. In this study, we systematically investigate the performance and assay correlations of PROTAC cell permeability assays and the chemical space in which these assays provide reliable results. Our work builds on a comprehensive data set of 3271 PROTACs spanning diverse chemical and target spaces, providing unprecedented coverage of PROTAC cell permeability data. These compounds were measured in up to three different types of assays: the NanoBRET E3 ligase target engagement assay, the Caco-2 assay, and a P-glycoprotein (P-gp) efflux liability assay. We find a strong correlation between readouts from the NanoBRET E3 ligase target engagement assay (availability shift) and those from the Caco-2 assay (apparent intrinsic permeability, basolateral-to-apical permeability, and efflux ratio), while P-gp liability derived from the P-gp assay cannot easily be translated to the Caco-2 efflux ratio. In the process, we also investigate the impact of physicochemical properties included in the Rule-of-Five on the applicability of the assays. Based on these findings, we derive guidelines and data-driven recommendations for the use of cell permeability assays in PROTAC optimization. While this study focuses on PROTACs, some of the observations may be relevant to other modalities with beyond-Rule-of-Five physicochemical properties.

Indexed as

Cell Membrane PermeabilityATP Binding Cassette Transporter, Subfamily B, Member 1Caco-2 CellsHumansProteolysisProteolysis Targeting ChimeraUbiquitin-Protein LigasesATP Binding Cassette Transporter, Subfamily B, Member 1Proteolysis Targeting ChimeraUbiquitin-Protein Ligasesassay correlationscaco-2cellular permeabilityNanoBRETP-gpPROTACs

Identifiers

PMID42203198
PMCPMC13343507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.